ISSN 1662-4009 (online)

ey0015.2-5 | Atypical forms of congenital hyperinsulinism are associated with increased expression of the transcription factor NKX2.2 and increased numbers of somatostain secreting cells | ESPEYB15

Atypical forms of congenital hyperinsulinism are associated with increased expression of the transcription factor NKX2.2 and increased numbers of somatostain secreting cells

B Han , Z Mohamed , MS Estebanez , RJ Craigie , M Newbould , E Cheesman , R Padidela , M Skae , M Johnson , S Flanagan , S Ellard , KE Cosgrove , I Banerjee , MJ Dunne

To read the full abstract: J Clin Endocrinol Metab. 2017 Sep 1;102(9):3261-3267At a histological level congenital hyperinsulinism (CHI) is classified into three forms, namely diffuse, focal and atypical. The atypical forms display histological mosacism (heterogeneous populations of islets, which appear to be resting or quiescent and localized to particular domains/lobes of the pancreas) but the m...

ey0015.15-5 | New treatments | ESPEYB15

15.5 Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia

CM Jones , A Mallappa , N Reisch , N Nikolaou , N Krone , BA Hughes , DM O'Neil , MJ Whitaker , JW Tomlinson , KH Storbeck , DP Merke , RJ Ross , W Arlt

To read the full abstract: J Clin Endocrinol Metab 2017;102:1797-1806We know that conventional glucocorticoid therapies fail to mimic the normal diurnal profile of cortisol secretion, which should show an early morning surge in circulating levels, followed by a gradual daytime reduction, and night-time suppression. The early morning surge in ACTH also drives adrenal androgen production, which is e...

ey0020.2-7 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.7. Weekly somapacitan is effective and well tolerated in children with GH deficiency: The randomized phase 3 REAL4 trial

BS Miller , JC Blair , MH Rasmussen , A Maniatis , RJ Kildemoes , J Mori , M Polak , RB Bang , V Bottcher , S Stagi , R Horikawa

Brief summary: This multicenter, randomized, controlled, phase 3 study compared the effects of long-acting GH (Somapacitan; 0.16 mg/kg/wk) with daily GH (Norditropin; 0.034 mg/kg/d), in GHD children. The trial was conducted over 52 weeks, followed by an ongoing 3-year single-group extension period. Similar efficacy and safety for somapacitan compared to daily GH was demonstrated over 52 weeks of treatment.Long-acting growth hormone (LAGH) formulations ha...

ey0018.8-3 | Important for Clinical Practice | ESPEYB18

8.3. Modified-release hydrocortisone in congenital adrenal hyperplasia

DP Merke , A Mallappa , W Arlt , A Brac de la Perriere , A Linden Hirschberg , A Juul , J Newell-Price , CG Perry , A Prete , DA Rees , N Reisch , N Stikkelbroeck , P Touraine , K Maltby , FP Treasure , J Porter , RJ Ross

J Clin Endocrinol Metab 2021; 106(5): e2063–e2077.https://pubmed.ncbi.nlm.nih.gov/33527139/The authors report the findings of a 6-month, randomized, phase 3 trial, with a single arm extension, to investigate the efficacy, safety and tolerability of modified release hydrocortisone (MC-HC) replacement therapy versus standard glucocorticoid replacement therapy in 122 adult patients with c...

ey0019.3-9 | New genes | ESPEYB19

3.9. Upregulation of GBP1 in thyroid primordium is required for developmental thyroid morphogenesis

RM Yang , M Zhan , QY Zhou , XP Ye , FY Wu , M Dong , F Sun , Y Fang , RJ Zhang , CR Zhang , L Yang , MM Guo , JX Zhang , J Liang , F Cheng , W Liu , B Han , Y Zhou , SX Zhao , HD Song

Genet Med. 2021 Oct;23(10):1944-1951. doi: 10.1038/s41436-021-01237-3. Epub 2021 Jun 30. PMID: 34194003Brief Summary: This genetic and developmental study identified pathogenic mutations in GBP1in patients with congenital hypothyroidism investigated by exome sequencing. In the zebrafish model, knockdown experiments revealed hypothyroidism and disordered thyroid morphology. These d...

ey0019.3-11 | Autoimmune Thyroid Disease | ESPEYB19

3.11. Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis

QY Zhang , XP Ye , Z Zhou , CF Zhu , R Li , Y Fang , RJ Zhang , L Li , W Liu , Z Wang , SY Song , SY Lu , SX Zhao , JN Lin , HD Song

Nat Commun. 2022 Feb 9;13(1):775. doi: 10.1038/s41467-022-28120-2. PMID: 35140214Brief Summary: This in vitro study identified interactions between distinct cell populations of the thyroid gland and immune cells in the context of Hashimoto thyroiditis. The authors provide important new insights into the pathological mechanism of Hashimoto thyroiditis by characterizing the stromal ...

ey0019.14-10 | Risk and Outcome | ESPEYB19

14.10. Childhood cardiovascular risk factors and adult cardiovascular events

DR Jr Jacobs , JG Woo , AR Sinaiko , SR Daniels , J Ikonen , M Juonala , N Kartiosuo , T Lehtimaki , CG Magnussen , JSA Viikari , N Zhang , LA Bazzano , TL Burns , RJ Prineas , J Steinberger , EM Urbina , AJ Venn , OT Raitakari , T Dwyer

N Engl J Med. 2022 May 19;386(20):1877–1888. doi: 10.1056/NEJMoa2109191.Brief summary: This prospective cohort study leveraged data from the International Childhood Cardiovascular Cohorts (i3C) Consortium, including 42 324 participants at baseline and followed-up over a mean of 35 years, in order to investigate associations between cardiovascular risk factors (CVRF, including body-mass ind...

ey0017.11-13 | Pharmacologic Treatment | ESPEYB17

11.13. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

EA Day , RJ Ford , BK Smith , P Mohammadi-Shemirani , MR Morrow , RM Gutgesell , R Lu , AR Raphenya , M Kabiri , AG McArthur , N McInnes , S Hess , G Pare , HC Gerstein , GR Steinberg

To read the full abstract: Nat Metab 2019;1:1202–1208.Metformin has become a mainstay in the treatment of T2DM in over six decades of clinical use and is today one of the world’s most commonly prescribed drugs. Anti-diabetic properties of metformin rely on an inhibition of hepatic glucose output through AMPK-dependent, but also AMPK-independent effects (reviewed in (1)). Neverthel...

ey0016.13-13 | Growth and Nutrition | ESPEYB16

13.13. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial

JH Humphrey , MNN Mbuya , R Ntozini , LH Moulton , RJ Stoltzfus , NV Tavengwa , K Mutasa , F Majo , B Mutasa , G Mangwadu , CM Chasokela , A Chigumira , B Chasekwa , LE Smith , JM Tielsch , AD Jones , AR Manges , JA Maluccio , AJ Prendergast

Lancet Glob Health 2019;7: e132–47. DOI: 10.1093/cid/civ844• This cluster-randomised, community-based trial investigates whether the combination of a water, sanitation and hygiene (WASH) intervention and of improved infant and young child feeding (IYCF) intervention improves stunting and anemia in children living in rural Zimbabwe.• Stunting decreased with ...

ey0020.8-11 | New Mechanisms | ESPEYB20

8.11. Soluble RAGE prevents type 1 diabetes expanding functional regulatory T cells

SS Leung , DJ Borg , DA McCarthy , TE Boursalian , J Cracraft , A Zhuang , AK Fotheringham , N Flemming , T Watkins , JJ Miles , PH Groop , JL Scheijen , CG Schalkwijk , RJ Steptoe , KJ Radford , M Knip , JM Forbes

Brief summary: using a murine model of diabetes and ex vivo experiments in human T-cell cultures, this study showed that short-term administration of an antagonist to the receptor for advanced glycation end products (sRAGE) modulates functional T regulatory cells (Treg) expansion and thus prevents diabetes.This study provides further support for a role of the advanced glycation end-product (AGEs)-AGE receptor (RAGE) pathways in the pathogenesis ...